Tango Therapeutics Shares Fall 14% After Pancreatic Cancer Study Results
An ongoing study found vopimetostat was not well tolerated at a certain dose level. Tango Therapeutics shares fell 14% to $24.13 on Friday.
By Kelly CloonanShares of Tango Therapeutics slid after an ongoing study showed its pancreatic cancer treatment wasn't well tolerated in a certain dose level.The stock fell 14% to $24.13 on Friday. Shares have more than doubled year to date.Tango said the drug, called vopimetostat, showed an 82% ob…